Methods of treating prostate cancer
The present application relates generally to methods for treating prostate cancer with substituted tricyclic derivative is 2-[3-(1,4-dimethyl-1H-1,2,3-triazol-5-yl)-5-[(S)-(oxan-4-yl)(phenyl)methyl]-5H-pyrido[3,2-b]indol-7-yl]propan-2-ol as a bromodomain inhibitor, or the pharmaceutically acceptable salt thereof.
1. A method of treating prostate cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of Compound A having the structure,
or a pharmaceutically acceptable salt thereof, and wherein the prostate cancer is castration resistant prostate cancer (CPRC), neuroendocrine prostate cancer (NEPC), anti-androgen resistant prostate cancer, or any combination thereof.
2. The method of claim 1 , wherein the prostate cancer is metastatic.
3. The method of claim 1 , wherein the prostate cancer to be treated is in an advanced stage.
4. The method of claim 1 , wherein the prostate cancer to be treated has metastasized to regions of the subject's body other than the prostate gland.
5. The method of claim 1 , wherein the prostate cancer to be treated has re-occurred in the subject following a significant period of remission.
6. The method of claim 1 , wherein the prostate cancer is castration resistant prostate cancer (CPRC).
7. The method of claim 6 , wherein the castration resistant prostate cancer (CPRC) is an androgen receptor (AR) independent disease characterized by neuroendocrine phenotype with a low or absent AR expression.
8. The method of claim 1 , wherein the prostate cancer is neuroendocrine prostate cancer (NEPC).
9. The method of claim 1 , wherein the method results in substantially inducing cell cycle arrest of the prostate cancer.
10. The method of claim 9 , wherein “substantially” is defined as at least about 50% cell cycle arrest of the prostate cancer.
11. The method of claim 1 , wherein the method results in completely inducing cell cycle arrest of the prostate cancer.
12. The method of claim 1 , wherein the method induces apoptosis of androgen independent cancer cells.
13. The method of claim 12 , wherein the method results in inducing about 20% or more apoptosis of the androgen independent cancer cells.
14. The method of claim 1 , wherein:
the method results in from about 70% to about 99% reduction of cancer cell proliferation.
15. The method of claim 1 , wherein:
the method results in from about 40% to about 99% reduction of tumor size.
16. The method of claim 1 , wherein the compound, or a pharmaceutically acceptable salt thereof, is adapted for oral administration.
17. The method of claim 16 , wherein the compound, or a pharmaceutically acceptable salt thereof, is in the form of a tablet, pill, sachet, or capsule of hard of soft gelatin.